Agios Pharmaceuticals Inc (STU:8AP)
€ 56 0 (0%) Market Cap: 3.20 Bil Enterprise Value: 2.30 Bil PE Ratio: 5.18 PB Ratio: 2.06 GF Score: 28/100

Agios Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 08:50PM GMT
Release Date Price: €32.8 (-2.96%)
Unidentified Analyst

Great. Good afternoon. I'll just read a disclosure statement first. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Okay. Well, great. And so, with that, I'm very pleased to have the senior management team from Agios here, starting with Brian Goff, newly minted CEO of the company; and Richa Poddar, Chief Commercial Officer; and Sarah Gheuens, Chief Medical Officer. So, great to have you.

And maybe, before we dive into some granular questions, since there's a lot going on at Agios, perhaps you can just give a high level as to status on some of the products, but also, I think, importantly, your background and your vision for the company.

Brian M. Goff
Agios Pharmaceuticals, Inc. - CEO & Director

Sure. No, thanks a lot, Jessica, and thanks for everybody who's joined us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot